DK1076559T3 - Cabergolin og pramipexol til behandling af CNS-sygdomme især Parkinson's sygdom - Google Patents
Cabergolin og pramipexol til behandling af CNS-sygdomme især Parkinson's sygdomInfo
- Publication number
- DK1076559T3 DK1076559T3 DK99919772T DK99919772T DK1076559T3 DK 1076559 T3 DK1076559 T3 DK 1076559T3 DK 99919772 T DK99919772 T DK 99919772T DK 99919772 T DK99919772 T DK 99919772T DK 1076559 T3 DK1076559 T3 DK 1076559T3
- Authority
- DK
- Denmark
- Prior art keywords
- cabergoline
- pramipexole
- treatment
- disease
- cns disorders
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Psychology (AREA)
- Psychiatry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Peptides Or Proteins (AREA)
- Plural Heterocyclic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US8561998P | 1998-05-15 | 1998-05-15 | |
| US8794398P | 1998-06-04 | 1998-06-04 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK1076559T3 true DK1076559T3 (da) | 2006-01-16 |
Family
ID=26772918
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK99919772T DK1076559T3 (da) | 1998-05-15 | 1999-05-07 | Cabergolin og pramipexol til behandling af CNS-sygdomme især Parkinson's sygdom |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US6503920B1 (da) |
| EP (1) | EP1076559B1 (da) |
| JP (1) | JP2002515425A (da) |
| KR (3) | KR20010043612A (da) |
| CN (1) | CN1301159A (da) |
| AT (1) | ATE310517T1 (da) |
| AU (1) | AU748629B2 (da) |
| BR (1) | BR9909917A (da) |
| CA (1) | CA2327299A1 (da) |
| DE (1) | DE69928521T2 (da) |
| DK (1) | DK1076559T3 (da) |
| EA (4) | EA200300125A1 (da) |
| ES (1) | ES2251191T3 (da) |
| HU (1) | HUP0101803A3 (da) |
| IL (1) | IL139682A0 (da) |
| NO (1) | NO20005757D0 (da) |
| NZ (2) | NZ526071A (da) |
| PL (1) | PL344574A1 (da) |
| SG (1) | SG121745A1 (da) |
| SK (1) | SK16272000A3 (da) |
| TR (1) | TR200003356T2 (da) |
| WO (1) | WO1999059563A2 (da) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0007309D0 (en) * | 2000-03-24 | 2000-05-17 | Pharmacia & Upjohn Spa | Crystalline form V|| of cabergoline |
| DE10053397A1 (de) | 2000-10-20 | 2002-05-02 | Schering Ag | Verwendung eines dopaminergen Wirkstoffes zur Behandlung von dopaminerg behandelbaren Erkrankungen |
| DE10043321B4 (de) * | 2000-08-24 | 2005-07-28 | Neurobiotec Gmbh | Verwendung eines transdermalen therapeutischen Systems zur Behandlung der Parkinsonschen Krankheit, zur Behandlung und Prävention des prämenstruellen Syndroms und zur Lactationshemmung |
| DE10064453A1 (de) * | 2000-12-16 | 2002-07-04 | Schering Ag | Verwendung eines dopaminergen Wirkstoffes zur Behandlung von dopaminerg behandelbaren Erkrankungen |
| DE10138275A1 (de) * | 2001-08-10 | 2003-02-27 | Boehringer Ingelheim Pharma | Verbindungen zur Beseitigung der Anhedonie |
| DE10148233A1 (de) * | 2001-09-28 | 2003-04-10 | Boehringer Ingelheim Pharma | Verbindungen zur Reduzierung übermäßiger Nahrungsaufnahme |
| US8679533B2 (en) | 2002-07-25 | 2014-03-25 | Pharmacia Corporation | Pramipexole once-daily dosage form |
| GB0221513D0 (en) | 2002-09-17 | 2002-10-23 | Generics Uk Ltd | Novel compounds and processes |
| CA2576386A1 (en) | 2004-08-13 | 2006-02-16 | Boehringer Ingelheim International Gmbh | Extended release pellet formulation containing pramipexole or a pharmaceutically acceptable salt thereof, method for manufacturing the same and use thereof |
| ATE486588T1 (de) | 2004-08-13 | 2010-11-15 | Boehringer Ingelheim Int | Tablettenformulierung mit verlängerter freisetzung mit pramipexol oder einem pharmazeutisch zulässigen salz davon, herstellungsverfahren und verwendung dafür |
| US20090041844A1 (en) * | 2006-02-10 | 2009-02-12 | Boehringer Ingelheim International Gmbh | Modified Release Formulation |
| PL232974B1 (pl) * | 2015-12-09 | 2019-08-30 | Ofta Spolka Z Ograniczona Odpowiedzialnoscia | Zastosowanie agonistów receptorów dopaminergicznych typu 2 w leczeniu schorzeń oczu wywołanych przez podwyższony poziom śródbłonkopochodnego czynnika wzrostu naczyń |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4526892A (en) * | 1981-03-03 | 1985-07-02 | Farmitalia Carlo Erba, S.P.A. | Dimethylaminoalkyl-3-(ergoline-8'βcarbonyl)-ureas |
| DE3937271A1 (de) * | 1989-11-09 | 1991-05-16 | Boehringer Ingelheim Kg | Transdermale applikation von 2-amino-6-n-propylamino-4,5,6,7-tetrahydrobenzothiazol |
| EP0664705B1 (en) * | 1993-08-18 | 2000-10-04 | Alcon Laboratories, Inc. | Compositions of ergoline derivatives for the treatment of glaucoma |
| US5496836A (en) * | 1994-05-05 | 1996-03-05 | Mount Sinai School Of Medicine Of The City University Of New York | Use of famotidine and related compounds in the treatment of movement disorders |
| FR2728374A1 (fr) * | 1994-12-15 | 1996-06-21 | Aerospatiale | Procede et dispositif pour fournir une information, alerte ou alarme pour un aeronef a proximite du sol |
| US5650420A (en) * | 1994-12-15 | 1997-07-22 | Pharmacia & Upjohn Company | Pramipexole as a neuroprotective agent |
-
1999
- 1999-05-07 PL PL99344574A patent/PL344574A1/xx not_active IP Right Cessation
- 1999-05-07 EA EA200300125A patent/EA200300125A1/ru unknown
- 1999-05-07 EA EA200300124A patent/EA200300124A1/ru unknown
- 1999-05-07 TR TR2000/03356T patent/TR200003356T2/xx unknown
- 1999-05-07 DK DK99919772T patent/DK1076559T3/da active
- 1999-05-07 IL IL13968299A patent/IL139682A0/xx unknown
- 1999-05-07 WO PCT/US1999/007024 patent/WO1999059563A2/en active IP Right Grant
- 1999-05-07 NZ NZ526071A patent/NZ526071A/en unknown
- 1999-05-07 HU HU0101803A patent/HUP0101803A3/hu unknown
- 1999-05-07 EA EA200200955A patent/EA200200955A1/ru unknown
- 1999-05-07 AU AU37419/99A patent/AU748629B2/en not_active Ceased
- 1999-05-07 EP EP99919772A patent/EP1076559B1/en not_active Expired - Lifetime
- 1999-05-07 CN CN99805219A patent/CN1301159A/zh active Pending
- 1999-05-07 NZ NZ508184A patent/NZ508184A/en unknown
- 1999-05-07 SK SK1627-2000A patent/SK16272000A3/sk unknown
- 1999-05-07 KR KR1020007012760A patent/KR20010043612A/ko not_active Application Discontinuation
- 1999-05-07 BR BR9909917-9A patent/BR9909917A/pt not_active Application Discontinuation
- 1999-05-07 AT AT99919772T patent/ATE310517T1/de not_active IP Right Cessation
- 1999-05-07 ES ES99919772T patent/ES2251191T3/es not_active Expired - Lifetime
- 1999-05-07 CA CA002327299A patent/CA2327299A1/en not_active Abandoned
- 1999-05-07 JP JP2000549228A patent/JP2002515425A/ja active Pending
- 1999-05-07 KR KR1020067007720A patent/KR20060056417A/ko not_active Application Discontinuation
- 1999-05-07 US US09/674,838 patent/US6503920B1/en not_active Expired - Fee Related
- 1999-05-07 KR KR1020067007719A patent/KR20060056416A/ko not_active Application Discontinuation
- 1999-05-07 SG SG200206791A patent/SG121745A1/en unknown
- 1999-05-07 EA EA200001192A patent/EA004474B1/ru not_active IP Right Cessation
- 1999-05-07 DE DE69928521T patent/DE69928521T2/de not_active Expired - Fee Related
-
2000
- 2000-11-14 NO NO20005757A patent/NO20005757D0/no unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK1632483T3 (da) | Heterocykliske, substituerede carbonylderivater og deres anvendelse som dopamin-D3-receptorligander | |
| BRPI0410296A (pt) | sistema e método para a determinação da eficácia de tratamento de distúrbios neurológicos utilizando o eletroencefalograma | |
| AU5584901A (en) | Use of cyclic gmp-specific phosphodiesterase inhibitors for treatment of parkinson's disease | |
| DK1076559T3 (da) | Cabergolin og pramipexol til behandling af CNS-sygdomme især Parkinson's sygdom | |
| DK0678023T3 (da) | Anvendelse af riluzol ved fremstilling af lægemidler til behandling af Parkinsons sygdom og parkinsonisme-syndromer | |
| NO20071267L (no) | Forhindring og behandling av synukleinopatiske og amyloidogene sykdommer | |
| DK1137762T3 (da) | Behandling af Pompes sygdom | |
| DK0927024T3 (da) | Indretning og fremgangsmåde til behandling af öjensygdomme | |
| TW200509968A (en) | Prevention and treatment of synucleinopathic disease | |
| EA200201247A1 (ru) | Соединения для лечения болезни альцгеймера | |
| DK0723444T3 (da) | Levobupivacain, som er egnet til behandling af kronisk smerte | |
| WO2002066469A3 (en) | Novel heterocyclic amide derivatives and their use as dopamine d3 receptor ligands | |
| PT912184E (pt) | Utilizacao de um derivado de k-252a para o tratamento de doencas do sietma nervoso central ou periferico e sobre-producao de citoquina | |
| FR2777781B1 (fr) | Associations riluzole et l-dopa pour le traitement de la maladie de parkinson | |
| MY135838A (en) | Methods for the treatment of mental disorders | |
| DK1392676T3 (da) | Hidtil ukendte heterocykliske urinstofderivater og deres anvendelse som dopamin -D3 - receptorligander | |
| HUP0300566A2 (hu) | Galantamin alkalmazása az Alzheimer-kórral összefüggő neuropszichiátriai viselkedésformák terápiájában | |
| BR0113646A (pt) | Tratamento de distúrbios inflamatórios | |
| DK0707477T3 (da) | Anvendelse af Efaxoran og derivater deraf til fremstilling af lægemidler beregnet til behandling af neurodegenerative sygdo | |
| MX9503363A (es) | N-(2,6-dioxo-3-piperidil) ftalimida (generico talidomida como tratamiento del sindrome de desgaste asociado con la infeccion por vih-1. | |
| HUP0401317A3 (en) | Novel use of subsituted aminomethyl chromans for the treatment of movement disorders and of adverse effects induced by drugs administered to treat extrapyramidal movement disorders | |
| DK1304107T3 (da) | Anvendelse af oxozolidinonderivater til behandling af psoriasis | |
| NO20050526L (no) | Bruk av PPAR-ALFA agonist for behandling av vektokning forbundet med PPAR-GAMMA-agonistbehandling | |
| DE60129846D1 (de) | Isochinolin-aroylpyrrole für die behandlung von krankheiten des zentralnervensystems |